期刊
ONCOIMMUNOLOGY
卷 8, 期 11, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2019.1648170
关键词
Non-small cell lung cancer; tumor infiltrating T cells; tumor reactivity; cytokines; polyfunctional T cells
资金
- Sanquin [PPOC-14-46]
- Stichting Sanquin Bloedvoorziening [PPOC 14-46]
Non-small cell lung cancer (NSCLC) is the second most prevalent type of cancer. With the current treatment regimens, the mortality rate remains high. Therefore, better therapeutic approaches are necessary. NSCLCs generally possess many genetic mutations and are well infiltrated by T cells (TIL), making TIL therapy an attractive option. Here we show that T cells from treatment naive, stage I-IVa NSCLC tumors can effectively be isolated and expanded, with similar efficiency as from normal lung tissue. Importantly, 76% (13/17) of tested TIL products isolated from NSCLC lesions exhibited clear reactivity against primary tumor digests, with 0.5%-30% of T cells producing the inflammatory cytokine Interferon (IFN)-gamma. Both CD4(+) and CD8(+) T cells displayed tumor reactivity. The cytokine production correlated well with CD137 and CD40L expression. Furthermore, almost half (7/17) of the TIL products contained polyfunctional T cells that produced Tumor Necrosis Factor (TNF)-alpha and/or IL-2 in addition to IFN-gamma, a hallmark of effective immune responses. Tumor-reactivity in the TIL products correlated with high percentages of CD103(+)CD69(+)CD8(+) T cell infiltrates in the tumor lesions, with PD-1(hi)CD4(+) T cells, and with FoxP3(+)CD25(+)CD4(+) regulatory T cell infiltrates, suggesting that the composition of T cell infiltrates may predict the level of tumor reactivity. In conclusion, the effective generation of tumor-reactive and polyfunctional TIL products implies that TIL therapy will be a successful treatment regimen for NSCLC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据